Background: Cetuximab and docetaxel have single-agent activity in squamous cell
carcinoma of the head and neck (SCCHN). The efficacy of their combination was evaluated …

6048 Background: Cetuximab and docetaxel are both active in squamous cell carcinoma of
the head and neck (SCCHN). We investigated the efficacy of cetuximab plus docetaxel as …

Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …

6032 Background: Platinum-based chemotherapy with cetuximab is the standard of care for
relapsed or metastatic squamous cell carcinoma of the head and neck (SCCHN). The aim of …

Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …

Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …

Simple Summary The purpose of the CET-MET trial was to find a new platinum-based
chemotherapy regimen in combination with cetuximab for relapsed or metastatic squamous …

5505 Background: Patients with R&M SCCHN have a poor prognosis. Patients failing first-
line therapy have few therapeutic options. Cetuximab (Erbitux) is an IgG1 monoclonal …

5513 Background: The goal of this study was to investigate the safety and efficacy of
cetuximab (Erbitux), an IgG1 monoclonal antibody targeting the EGFR, given in combination …

5502 Background: Pts with refractory SCCHN have a poor prognosis with few therapeutic
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …